Johnson & Johnson
JNJ.SW News Today: Stay Updated with the Latest Johnson & Johnson News in Real Time
Find JNJ.SW news now at Meyka AI. Stay informed with the latest Johnson & Johnson stocks updates, including price news, market analysis, and expert insights.
RBRI (RBR Global Inc., PNK) falls 98.80% on 10 Mar 2026: downside and outlook
RBRI stock tumbles to **$0.012** on 10 Mar 2026; outlook, Meyka AI forecast and risks for RBR Global Inc.
March 9: House GOP Heads to Florida as One-Vote Majority Tests Agenda
House GOP retreat in Florida arrives as Speaker Mike Johnson manages a one-vote majority, heightening gridlock and headline risk for investors ahead of the 2026 midterms.
March 9: Mortgage Officer Hiring Heats Up as Movement Adds Top Producer
Mortgage officer hiring accelerates as Movement Mortgage adds top producer Todd Johnson and plans 27 hires for early 2026. What this means for investors this spring.
Mortgage Officers March 7: Movement Mortgage Adds Top Producer in Midwest
Movement Mortgage adds top 1% producer Todd Johnson and plans early 2026 onboarding of 27 loan officers, signaling strong mortgage officer hiring and Midwest growth.
March 6: Andrew Paul Johnson Life Term Rekindles Trump Pardon Risk
Andrew Paul Johnson’s life sentence in Florida reignites questions about Trump pardon policy and election-year risk. Here is what the case means for law, politics, and markets.
NANO.PA Nanobiotix S.A. EURONEXT up 18.41% intraday 05 Mar 2026: Momentum tied to clinical progress
Intraday top gainer NANO.PA stock jumps to €31.20 on 05 Mar 2026; Meyka AI grade, forecast and catalysts explained
March 04: Newsom’s $291M CARE Court Push Shifts County Funding
Gov. Gavin Newsom directs $291 million to homelessness and mental health under CARE Court, tying funds to results. What this shift means for California counties and muni investors.
Moderna Settles COVID Vaccine Patent Dispute for Up to $2.25 Billion
In a major development for the biotech industry and global health sector, Moderna has agreed to settle a long running COVID Vaccine patent dispute for up to $2.25 billion. The agreement closes a key legal battle linked to its blockbuster mRNA based COVID 19 vaccine, widely known as Spikevax. This settlement is one of the…
JNJ Stock Today: 52-Week High Test on $20B DePuy Sale Talk – March 02
Johnson & Johnson stock nears a 52-week high on $20B DePuy Synthes sale talk and strength in oncology and immunology. See catalysts, valuation, and key levels.